**Supplementary Table 2. Disease Characteristics and Medical History at Baseline for Patients Enrolled in EAMS Who Consented to Observational Research**

|  | **Patients Enrolled in EAMS** **Who Consented to** **Observational Research** **(N=113)** |
| --- | --- |
| **Number of prior or pre-existing comorbidities at therapy initiation, n (%)** | **N=110** |
| 0 | 48 (43.6) |
| 1 | 31 (28.2) |
| 2 | 12 (10.9) |
| 3 or more | 19 (17.3) |
| **Most common prior or pre-existing comorbidities at therapy initiationa, n (%)** | **N=110** |
| Hypertension | 20 (18.2) |
| ‘Other’ cardiovascular | 14 (12.7) |
| VTE/pulmonary embolism | 12 (10.9) |
| **Concomitant medications, n (%)** | **N=110** |
| Yes | 96 (87.3) |
| No | 14 (12.7) |
| **Most common types of concomitant medicationsa, n (%)** | **N=110** |
| Proton pump inhibitors | 69 (62.7) |
| Opioid analgesics | 35 (31.8) |
| Antiemetic drugs | 23 (20.9) |
| Antithrombotic drugs | 22 (20.0) |
| Non-opioid analgesics | 21 (19.1) |
| Lipid monitoring agents | 15 (13.6) |
| Agents acting on the renin-angiotensin system | 14 (12.7) |
| Beta blocking agents | 13 (11.8) |
| Vitamins minerals and food supplements | 11 (10.0) |
| **Tumour histology (adenocarcinoma), n (%)** | **N=113** |
| Yes | 112 (99.1) |
| No | 1 (0.9) |

a ‘Most common’ reported comorbidities and concomitant medications are those that were reported in at least 10% of patients who consented to observational research. More than one comorbidity or concomitant medication may have been reported per patient.

Abbreviations: EAMS = Early Access to Medicines Scheme; VTE = venous thromboembolism